MAPT and Alzheimer disease: In conclusion, we review the different sites and mechanisms of action of drugs that regulate Aβ and tau aggregation, suggesting that the development of compounds that dual-target Aβ and tau aggregation based on these mechanisms may be a promising therapeutic strategy for AD.